CDC20 Antibodies

Background

CDC20 is a crucial cell cycle regulatory factor, mainly functioning as an activating subunit to participate in the activation of the late-promoting complex/cyclosome (APC/C), thereby regulating the correct separation of chromosomes during mitosis. This protein ensures the smooth transition of the cell cycle from the middle stage to the later stage by mediating the ubiquitination degradation of substrates such as cyclin B and securin. In the early 1990s, CDC20 was discovered to be an important regulatory factor in the cell cycle process, and its abnormal function can lead to chromosomal instability and aneuploidy formation. Subsequent studies have shown that CDC20 is abnormally highly expressed in various malignant tumors, not only participating in the occurrence and development of tumors, but also affecting the sensitivity to radiotherapy and chemotherapy by regulating apoptosis, autophagy, and the immune microenvironment. Its highly conserved and precise regulatory mechanism makes it a potential important target for cancer diagnosis and treatment, providing a key molecular basis for in-depth understanding of the relationship between cell cycle regulation and tumor occurrence.

Structure Function Application Advantage Our Products

Structure of CDC20

The molecular weight of the CDC20 protein is approximately 55 kDa. Due to selective splicing and post-translational modifications, it varies slightly among different species.

Species	Human	Mouse	Rat	Xenopus	Fruit Fly
Molecular Weight (kDa)	55	55	55	55	55
Primary Structural Differences	Contains WD40 domain and C-box	Highly homologous to humans	Stronger in activating APC/C activity	High expression during embryonic development	Highly conserved functional domain

This protein is composed of 499 amino acids and mainly includes the N-terminal C-box, the middle WD40 repeat sequence, and the C-terminal IR tail. In its three-dimensional structure, the WD40 domain folds into a β-propeller conformation, forming 7 blade-like repeating units, serving as the substrate recognition platform. The C-box mediates the binding with the APC/C complex, and the IR tail participates in substrate docking. These structural features enable CDC20 to specifically recognize cyclins containing D-box or KEN-box, ensuring the precise transition from mitotic midphase to late phase.

Fig. 1 Cell division cycle 20 homologue (CDC20) domains and motifs.¹

Key structural features of CDC20:

The N-terminal C-box domain mediates binding to the APC/C complex
The WD40 domain forms a β-propeller substrate recognition platform
The C-terminal IR tail is involved in substrate docking and release
The conserved KEN-box and D-box recognition motifs ensure substrate specificity

Functions of CDC20

The core function of CDC20 is to initiate the mitotic metaphase stage, but it is also involved in the regulation of cell cycle checkpoints and the maintenance of genomic stability.

Function	Description
APC/C activation	As the activating subunit, it binds to APC/C, mediates the degradation of cyclin B and securin, and promotes the transition from metaphase to anaphase of mitosis.
Spindle checkpoint regulation	Responds to improperly attached chromosomes, delays the initiation of anaphase until all chromosomes are correctly aligned.
Substrate recognition	Specifically recognizes the D-box and KEN-box sequences of substrate proteins through the WD40 domain to ensure precise degradation timing.
Genomic stability maintenance	Ensures equal segregation of chromosomes and prevents the formation of aneuploidy.
Apoptosis regulation	Influences the cell survival decision by degrading pro-apoptotic factors or stabilizing anti-apoptotic proteins.

The activity of CDC20 is strictly regulated by the spindle assembly checkpoint, and the balance between its transient activation and continuous expression determines the fate of the cell.

Applications of CDC20 and CDC20 Antibody in Literature

1. Xian, Feng, et al. "The potential role of CDC20 in tumorigenesis, cancer progression and therapy: A narrative review." Medicine 102.36 (2023): e35038. https://doi.org/10.1097/MD.0000000000035038

The article indicates that CDC20 regulates the cell cycle in solid cancers, and its dysregulation is associated with tumor occurrence, drug resistance, and poor prognosis. This factor also affects apoptosis, the immune microenvironment, and angiogenesis, and is expected to become a biomarker and therapeutic target for cancer diagnosis and treatment.

2. Bruno, Samantha, et al. "CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies." Journal of Experimental & Clinical Cancer Research 41.1 (2022): 159. https://doi.org/10.1186/s13046-022-02363-9

The article indicates that CDC20 not only regulates mitosis to ensure chromosome separation, but also participates in apoptosis, stemness and immune infiltration. It is highly expressed in hematological malignancies and is related to prognosis. Inhibitors targeting CDC20 have shown potential for treating lymphoma and multiple myeloma.

3. Zhao, Shuai, et al. "CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway." International journal of biological sciences 17.13 (2021): 3608. https://doi.org/10.7150/ijbs.64003

The article indicates that CDC20 is highly expressed in liver cancer. Knockdown of CDC20 can enhance the efficacy of radiotherapy. It inhibits proliferation, aggravates DNA damage and promotes apoptosis through the P53 and Bcl-2/Bax pathways. Targeting CDC20 is expected to enhance the radiosensitivity of liver cancer.

4. Wu, Fei, et al. "Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer." Experimental hematology & oncology 12.1 (2023): 67. https://doi.org/10.1186/s40164-023-00428-9

The article indicates that CDC20 is highly expressed in prostate cancer and inhibits pyroptosis by mediating the ubiquitination and degradation of GSDME. Knockdown or inhibition of CDC20 can promote GSDME-dependent anti-tumor immunity and synergistically enhance the effect when combined with PD-1 antibodies.

5. Fan, Yizeng, et al. "CDC20‐Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma." Advanced Science 12.5 (2025): 2412967. https://doi.org/10.1002/advs.202412967

The article indicates that CDC20 mediates the K27 ubiquitination of PBRM1 and its degradation through the autophagy pathway. Targeting this process can induce M1 macrophage polarization and enhance the efficacy of PD-1 immunotherapy for renal cancer.

Creative Biolabs: CDC20 Antibodies for Research

Creative Biolabs specializes in the production of high-quality CDC20 antibodies for research and industrial applications. Our portfolio includes monoclonal and polyclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

Custom CDC20 Antibody Development: Tailor-made solutions to meet specific research requirements.
Bulk Production: Large-scale antibody manufacturing for industry partners.
Technical Support: Expert consultation for protocol optimization and troubleshooting.
Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CDC20 antibodies, custom preparations, or technical support, contact us at email.

Reference

Xian, Feng, et al. "The potential role of CDC20 in tumorigenesis, cancer progression and therapy: A narrative review." Medicine 102.36 (2023): e35038. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1097/MD.0000000000035038